Selank
Overview
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analog of the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg). It is approved in Russia as an anxiolytic and nootropic medication. Its unique profile combines anxiolytic activity without sedation, cognitive enhancement, and immune modulation derived from its tuftsin backbone, distinguishing it from classical benzodiazepine anxiolytics.
A synthetic heptapeptide developed as a stabilized analog of the endogenous immune peptide tuftsin, studied in pre-clinical models.
Primary research focus
- Anxiolytic-mechanism research (studied without sedation)
- Cognitive function — attention, memory, processing
- Stress-axis modulation and immune-signaling research
Mechanism of Action
Selank modulates GABAergic neurotransmission indirectly, without directly binding GABA-A receptors like benzodiazepines. Published research indicates it affects the balance of inhibitory and excitatory neurotransmission through allosteric modulation of GABA receptor sensitivity. It also influences enkephalin degradation enzymes, increasing enkephalin availability. Additionally, Selank has been shown to upregulate BDNF (brain-derived neurotrophic factor) expression, modulate serotonergic and dopaminergic signaling, and influence gene expression related to neurotransmitter pathways. Its tuftsin-derived structure also confers immune-modulatory properties through effects on monocyte and T-cell function.
Research-Indicated Benefits
- Published research suggests anxiolytic effects comparable to benzodiazepines without sedation, tolerance, or dependence in animal models
- Published research suggests improvements in attention, memory, and cognitive processing in animal learning paradigms
- Published research suggests modulation of the HPA (hypothalamic-pituitary-adrenal) stress axis
- Published research suggests immune-modulatory activity through its tuftsin backbone, including effects on IL-6 and T-cell cytokine profiles
- Published research suggests neuroprotective properties through BDNF upregulation and enkephalin pathway modulation
Typical Research Protocols
Commonly reported in research literature: 250-500 mcg administered intranasally, typically 2-3 times daily due to the short half-life (~30 minutes). Intranasal administration is the primary route in published Russian clinical protocols, offering direct CNS access via the olfactory pathway. Subcutaneous administration has also been referenced in research. Published treatment durations in Russian clinical literature typically span 2-4 weeks.
Safety Profile
Published Russian clinical data reports a favorable safety profile with no significant adverse effects at therapeutic doses. No sedation, cognitive impairment, withdrawal symptoms, or dependence have been reported, distinguishing Selank from benzodiazepine anxiolytics. Independent Western replication of safety data is limited. No significant changes in liver enzymes, renal function, or hematological parameters have been reported in the published clinical literature.
Key Studies
- Andreeva LA, et al. Foundational research on Selank synthesis and pharmacology at the Russian Academy of Sciences.
- Kozlovskii II, Danchev ND. "The optimizing action of the synthetic peptide selank on a conditioned active avoidance reflex in rats." Neuroscience and Behavioral Physiology, 2003.
- Seredenin SB, et al. Multiple studies investigating Selank anxiolytic pharmacology published in Russian pharmacology journals.
- Uchakina ON, et al. Studies on Selank immunomodulatory effects published in immunology journals.
- Zozulya AA, et al. Studies on Selank effects on anxiety and stress markers in clinical populations.
Interactions and Stacking
Semax is the most commonly discussed combination partner, offering complementary nootropic mechanisms (Semax targets BDNF/cholinergic pathways; Selank targets GABAergic/anxiolytic pathways). Both are Russian-developed intranasal peptides and are frequently co-administered in published research protocols. DSIP provides complementary stress and sleep modulation through different neuroendocrine pathways. Thymosin-Alpha-1 shares immune-modulatory research interest through distinct receptor systems.
For research and educational purposes only. Not medical advice.
Frequently Asked Questions
Is Selank FDA-approved?
No. Selank is not approved by the U.S. Food and Drug Administration for any clinical application. It remains classified as a research compound supplied for laboratory work only.
What does the research literature show about Selank?
The published research record for Selank is summarized in the body of this article and the citations section. Pre-clinical and animal-model studies make up the bulk of the literature; human trial data is limited and is noted explicitly where it exists.
What are the documented synergistic compounds for Selank research?
See the Related Research sidebar for compounds that appear alongside Selank in the published literature. Detailed synergy notes will populate during the next vault expansion pass.
Where can I source Selank for research purposes?
See the Where to Source section above for vendors that supply research-grade Selank. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.
Is Selank safe for human or animal use?
Selank is sold for in vitro and laboratory research only. It is not intended for human or veterinary administration, and no safety determination for such use has been established by the U.S. Food and Drug Administration or any equivalent regulatory body.